• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结节病患者:对碳酸酐酶抑制剂的意外反应。

Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.

作者信息

Khedr Yahya A H, Khedr Abdulla H

机构信息

Faculty of Medicine, Ophthalmology, Ain Shams University, Cairo, Egypt.

出版信息

BMJ Case Rep. 2013 Jul 26;2013:bcr2013200391. doi: 10.1136/bcr-2013-200391.

DOI:10.1136/bcr-2013-200391
PMID:23893285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3736246/
Abstract

Ocular diseases are very common in many of the systemic diseases such as sarcoidosis, and may sometimes be the presenting symptom of the disease. In this case report, we present an unusual reaction of the sarcoid granuloma to carbonic anhydrase enzyme inhibitors (CAIs), which was encountered in a patient with ocular sarcoidosis. This observation was taken after a 2-week interval between a CT scan orbits and an MRI orbits which showed a decrease in size from 4×3×4 cm to 2.5×2.5×2 cm, respectively. We suspected the dorzolamide CAI to have had a significant role in the reduction in size. It is suggested that acidotic changes that occur due to the effect of the carbonic anhydrase inhibitor causes electrolyte imbalance, intracellular as well as extracellular, which lead to the reduction in the size of the granuloma.

摘要

眼部疾病在许多全身性疾病(如结节病)中非常常见,有时可能是该疾病的首发症状。在本病例报告中,我们呈现了结节病肉芽肿对碳酸酐酶抑制剂(CAIs)的一种不寻常反应,此反应出现在一名眼部结节病患者身上。这一观察结果是在眼眶CT扫描和眼眶MRI扫描间隔2周后得出的,扫描结果显示肿物大小分别从4×3×4厘米减小至2.5×2.5×2厘米。我们怀疑多佐胺CAI在肿物缩小过程中起到了重要作用。有人提出,碳酸酐酶抑制剂的作用导致的酸中毒变化会引起细胞内和细胞外的电解质失衡,进而导致肉芽肿体积减小。

相似文献

1
Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.结节病患者:对碳酸酐酶抑制剂的意外反应。
BMJ Case Rep. 2013 Jul 26;2013:bcr2013200391. doi: 10.1136/bcr-2013-200391.
2
Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.从全身用碳酸酐酶抑制剂转为局部用多佐胺:对有药物相关副作用的青光眼患者生活质量的影响。
Isr Med Assoc J. 2003 Apr;5(4):260-3.
3
Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.新型活性局部碳酸酐酶抑制剂多佐胺的四周安全性和疗效研究。
Arch Ophthalmol. 1993 Oct;111(10):1343-50. doi: 10.1001/archopht.1993.01090100051026.
4
Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor.多佐胺:一种局部碳酸酐酶抑制剂的研发与临床应用
Surv Ophthalmol. 1997 Sep-Oct;42(2):137-51. doi: 10.1016/s0039-6257(97)00053-2.
5
Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.局部碳酸酐酶抑制剂在青光眼和高眼压症中的视觉功能。
Curr Med Res Opin. 2010 Jun;26(6):1255-67. doi: 10.1185/03007991003738485.
6
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.局部碳酸酐酶抑制剂的药理及降眼压特性。
Prog Retin Eye Res. 2000 Jan;19(1):87-112. doi: 10.1016/s1350-9462(99)00006-3.
7
Topical carbonic anhydrase inhibitors.局部碳酸酐酶抑制剂。
Curr Opin Ophthalmol. 1997 Apr;8(2):2-6. doi: 10.1097/00055735-199704000-00002.
8
[Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide].[在洗眼液中使用碳酸酐酶抑制剂治疗青光眼:多佐胺的中期回顾性经验]
Bull Soc Belge Ophtalmol. 1997;267:157-66.
9
Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.局部用与口服碳酸酐酶抑制剂治疗小儿青光眼
J AAPOS. 1998 Feb;2(1):43-7. doi: 10.1016/s1091-8531(98)90109-4.
10
[Topical carbonic anhydrase inhibitors in the treatment of glaucoma].[局部碳酸酐酶抑制剂在青光眼治疗中的应用]
J Fr Ophtalmol. 1996;19(5):357-62.

本文引用的文献

1
Ocular involvement in sarcoidosis.结节病的眼部受累情况。
Br J Ophthalmol. 2000 Jan;84(1):110-6. doi: 10.1136/bjo.84.1.110.
2
Systemic sarcoidosis with bilateral orbital involvement: MR findings.双侧眼眶受累的系统性结节病:磁共振成像表现
AJNR Am J Neuroradiol. 1998 Feb;19(2):336-7.